

1 **The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta**  
2 **virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA**  
3 **vaccine boost are comparable to those after double immunisation with mRNA vaccines**

4 Ruben Rose <sup>1,†</sup>, Franziska Neumann <sup>2,†</sup>, Olaf Grobe <sup>2</sup>, Thomas Lorentz <sup>2</sup>, Helmut Fickenscher <sup>1</sup>,  
5 Andi Krumbholz <sup>1,2,\*</sup>

6 1 Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum  
7 Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany

8 2 Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany

9 \* Correspondence: krumbholz@infmed.uni-kiel.de; Tel.: +49-431-22010131

10 † These first authors contributed equally

11 **Abstract**

12 **Background:** The humoral immune response after primary immunisation with a SARS-CoV-2 vector  
13 vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost  
14 (Pfizer/BioNTech, BNT162b2; Moderna, m-1273) was examined and compared with the antibody  
15 response after homologous vaccination schemes (AZD1222/AZD1222 or BNT162b2/BNT162b2).

16 **Methods:** Sera from 59 vaccinees were tested for anti-SARS-CoV-2 immunoglobulin G (IgG) and virus-  
17 neutralising antibodies (VNA) with four IgG assays, a surrogate neutralisation test (sVNT), and a Vero  
18 cell-based neutralisation test (cVNT) using the B.1.1.7 variant of concern (VOC; alpha) as antigen.  
19 Investigation was done before and after heterologous (n=31 and 42) or homologous booster  
20 vaccination (AZD1222/AZD1222, n=8/9; BNT162b2/BNT162b2, n=8/8). After the second immunisation,  
21 26 age and gender matched sera (AZD1222/mRNA, n=9; AZD1222/AZD1222, n=9;  
22 BNT162b2/BNT162b2, n=8) were also tested for VNA against VOC B.1.617.2 (delta) in the cVNT. The  
23 strength of IgG binding to separate SARS-CoV-2 antigens was measured by avidity.

24 **Results:** After the first vaccination, prevalence of IgG directed against (trimeric) SARS-CoV-2 spike (S)-  
25 protein and its receptor-binding domain (RBD) varied from 55-95 % (AZD1222) to 100% (BNT162b2),  
26 depending on the vaccine used and the SARS-CoV-2 antigen used. The booster vaccination resulted in  
27 100 percent seroconversion and appearance of highly avid IgG as well as VNA against VOC B.1.1.7. The  
28 results of the anti-SARS-CoV-2 IgG tests showed an excellent correlation to the VNA titres against this  
29 VOC. The agreement of cVNT and sVNT results was good. However, the sVNT seems to overestimate  
30 non and weak B.1.1.7-neutralising titres. The mean anti-SARS-CoV-2 IgG and B.1.1.7-neutralising titres  
31 were significantly higher after heterologous vaccination compared to the homologous AZD1222  
32 scheme. If VOC B.1.617.2 was used as antigen, significantly lower mean VNAs were measured in the  
33 cVNT, and three (33.3%) vector vaccine recipients had a VNA titre <1:10.

34 **Conclusions:** The heterologous SARS-CoV-2 vaccination leads to a strong antibody response with anti-  
35 SARS-CoV-2 IgG and VNA titres at a level comparable to that of a homologous BNT162b2 vaccination  
36 scheme. Irrespectively of the chosen immunisation regime, highly avid IgG antibodies can be detected

37 just two weeks after the second vaccine dose indicating the development of a robust humoral  
38 immunity. The observed reduction in the VNA titre against VOC B.1.617.2 is remarkable and may be  
39 attributed to a partial immune escape of the delta variant.

40 **Keywords:** COVID-19; vaccination schemes; immunoglobulin G; maturity process; virus variants of  
41 concern; virus-neutralisation

42

### 43 **Background**

44 Since spring 2020 the pandemic caused by the *severe acute respiratory syndrome coronavirus 2* (SARS-  
45 CoV-2) [1] is ongoing and represents a global challenge. The availability of safe and effective  
46 vaccinations are seen as one of the most important pillars in containing the pandemic [2, 3]. Within a  
47 few months, the intensive research activities led to the development of several highly effective SARS-  
48 CoV-2 vaccines [4, 5, 3]. In addition to the induction of cellular immunity, their administration should  
49 stimulate the formation of virus-neutralising antibodies (VNA) that bind to epitopes of the viral spike  
50 (S)-protein and its receptor binding domain (RBD) and, thus, prevent the cells from being infected [6,  
51 7, 3].

52 Four SARS-CoV-2 vaccines have received conditional approval in the European Union. These vaccines  
53 are based on two different technologies [8]. For the messenger ribonucleic acid (mRNA) vaccines from  
54 Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), the genetic information for the S-protein  
55 was genetically optimised and the mRNA was packaged in liposomes. After inoculation, the muscle  
56 cells directly expressed this stable and highly immunogenic viral surface protein [2, 6]. In vector  
57 vaccines, replication-deficient human (Ad26.CO2; Janssen) or chimpanzee adenoviruses (ChAdOx1  
58 nCoV-19/AZD1222, Vaxzevria; AstraZeneca, hereinafter referred to as AZD1222) are used to introduce  
59 the genetic information of the SARS-CoV-2 S-protein into the cells, followed by transcription of  
60 deoxyribonucleic acid into mRNA and expression of the S-protein [2, 6].

61 Due to the widespread use of these vaccines, rare and sometimes unexpected side effects have been  
62 reported. Particularly noteworthy are cases of immune thrombotic thrombocytopenia, which  
63 predominantly occurred in women under 50 years of age within one month after the initial vaccination  
64 with AZD1222 [5]. Many of these patients developed cerebral sinus venous thrombosis or splanchnic  
65 vein thrombosis and presented antibodies to platelet factor 4 but without previous exposure to  
66 heparin [5]. Due to this rare but serious side effect, AZD1222 is no longer unreservedly recommended  
67 by the Standing Vaccination Commission (STIKO) of the Robert Koch Institute for individuals under 60  
68 years of age. The STIKO suggests that a vaccination with AZD1222 that has already started should be  
69 completed with an mRNA vaccine [9, 10]. Due to the sharp increase in the delta variant of concern  
70 (VOC; Pango-lineage [11] B.1.617.2) in Germany, the STIKO has revised its recommendations once  
71 more. Since July 1<sup>st</sup> 2021, all AZD1222 first vaccinated persons have been recommended to complete  
72 the second vaccination with an mRNA vaccine [12]. Animal experiments indicated very good humoral  
73 and cellular immunity after heterologous vaccination [13, 14]. There is, however, so far limited  
74 knowledge on the benefit of the heterologous vaccination scheme in humans. First results indicated a

75 higher prevalence of short-lived side effects following the heterologous boost dose compared to the  
76 homologous counterpart [15]. Meanwhile, a few studies have been published for the immunogenicity  
77 of the AZD1222/mRNA vaccine regimen [16-21].

78 In this report, we compare the SARS-CoV-2 specific immunoglobulin G (IgG) response after  
79 heterologous immunisation with that elicited by homologous vaccination schedules. We also focus on  
80 the developing anti-SARS-CoV-2 IgG avidity as a parameter for IgG maturity and binding strength.  
81 Finally, we use various methods to investigate the development of VNA against two prevalent VOCs.  
82 Therefore, humoral immunity induced by vaccines is being extensively studied. We believe that the  
83 results obtained in this study will help to better understand the effects and possibly benefits of a  
84 heterologous vaccination regimen.

85

## 86 **Methods**

87 The anti-S and anti-RBD IgG response after heterologous immunisation with a SARS-CoV-2 vector  
88 vaccine as prime and an mRNA vaccine as boost was compared to that after homologous vaccination  
89 with vector or mRNA vaccines. This setting also includes monitoring of IgG avidity and of virus-  
90 neutralising capacities. Forty-seven female and twelve male vaccinees with a median age of 31 years  
91 (age span 18 – 61 years) were recruited for this study and gave their informed consent. Forty-two of  
92 them received a heterologous immunisation scheme (N=41, AZD1222/BNT162b2; N=1,  
93 AZD1222/mRNA-1273), while nine and eight vaccinees received a homologous scheme of the vector  
94 vaccine AZD1222 or the mRNA vaccine BNT162b2, respectively. The first blood sample was taken  
95 immediately before the second vaccination and the second about two weeks later. For several  
96 individuals no serum was available before or after the booster vaccination (Table 1). The ethics  
97 committee of the medical faculty of the Christian-Albrechts-Universität zu Kiel (Kiel, Germany)  
98 approved the study design (D467/20, 16.04.2020, amendment 02.02.2021). We examined the early  
99 humoral immune response (other samples obtained a few days to weeks after the initial immunisation  
100 with AZD1222) of most of the subjects in a previous study. In addition, sera obtained from three  
101 vaccinees after the initial immunisation with BNT162b2 (N=2) and AZD1222 (N=1) have already been  
102 tested in frame of the previous study [22]. In this respect, we consider it justified to include these  
103 individuals (and few sera) in the present report and to demonstrate the results before and after the  
104 booster vaccination.

### 105 *Anti-SARS-CoV-2 specific IgG immunoassays*

106 The sera were tested with the SERION ELISA agile SARS-COV-2 IgG assay (S-protein as antigen; Institut  
107 Virion\Serion GmbH, Würzburg, Germany) and the Abbott SARS-CoV-2 IgG II Quant assay (RBD as  
108 antigen; Abbott, Wiesbaden, Germany) as described previously [22]. In addition, the LIAISON® SARS-  
109 CoV-2 Trimeric S IgG assay was included as a further assay on a LIAISON® XL system (both Diasorin  
110 S.p.A, Saluggia, Italy). According to the manufacturer, this quantitative chemiluminescence  
111 immunoassay detects IgG directed against the trimeric S-protein and has an excellent clinical sensitivity  
112 and specificity of 98.7% and 99.5%, respectively. The high diagnostic value of this test has also been

113 demonstrated in a recent seroprevalence study [23]. The results of the three IgG assays were given in  
114 Binding Antibody Units (BAU) per milliliter (ml), using the manufacturer's conversion factors, which  
115 were based on measurements of the WHO International Standard Anti-SARS-CoV-2 Immunoglobulin  
116 (NIBSC code 20-136) [24]. As in our previous studies, we generally rate borderline test results as  
117 positive [25, 22].

#### 118 *Anti-SARS-CoV-2 IgG immunoblots including measurement of IgG avidities*

119 All sera were tested with and without avidity reagent in the *recomLine* SARS-CoV-2 IgG assay (Mikrogen  
120 GmbH, Neuried, Germany) as reported previously [25, 22]. The strength of SARS-CoV-2 antigen binding  
121 against the S1-and RBD-subunits of the S-protein and against the nucleoprotein (NP, if detectable) was  
122 assigned to the categories low (= 1), intermediate (= 2), and high (= 3) [22].

#### 123 *Measurement of SARS-CoV-2-neutralising antibodies*

124 The sera were examined for their virus-neutralising capacities. First, a surrogate assay was used (TECO®  
125 SARS-CoV-2 Neutralisation Antibody ELISA; TECOmedical AG, Sissach, Switzerland). In this competitive  
126 assay, the human angiotensin-converting enzyme 2 (ACE-2) was attached to the solid phase while  
127 peroxidase-conjugated RBD was present in the liquid phase. If the human serum contained RBD-  
128 specific antibodies, binding of RBD to ACE-2 was prevented. Hence, after washing steps the color  
129 reaction turned out to be weaker compared to a RBD-antibody-free serum sample. According to the  
130 manufacturer, it is assumed from an inhibition of 20% that VNA are present [22].

131 Second, dilutions of each serum were tested in triplicate in a laboratory-developed Vero cell-based  
132 neutralisation assay (cVNT). This 96-well format cVNT uses two own SARS-CoV-2 isolates (alpha, VOC  
133 B.1.1.7; delta, VOC B.1.617.2) obtained after cultivation of clinical samples in Vero cells as described  
134 previously [26]. A dilution >1:10 was considered likely protective [25, 22].

#### 135 *Data evaluation and statistical calculations*

136 Data were statistically analysed by help of the GraphPad Prism version 9.1.2 software (GraphPad  
137 Software, San Diego, CA, USA). In most cases, the Kruskal-Wallis test, an adjusted, non-paired and non-  
138 parametric test was applied. The Wilcoxon test, a paired non-parametric test, was chosen to compare  
139 the mean VNA titre differences against VOC B.1.1.7 and VOC B.1.617.2. The level of significance was  
140 generally set at 0.05. Furthermore, we calculated the Pearson correlation coefficient  $r$  to demonstrate  
141 the linear correlation between separate data sets. We used a simple logistic regression to determine  
142 the probability of detecting VNA with our cVNT as a function of the anti-SARS-CoV-2 IgG or sVNT  
143 results.

144

145

146 **Results**

147 *Composition of the study groups*

148 This study included 59 individuals. Nine and eight of them received a homologous immunisation with  
 149 AZD1222 or BNT162b2, respectively, while 42 received a heterologous vaccination. The composition  
 150 of the study groups including median age, age range, gender and median time of blood collection in  
 151 days is shown in Table 1.


152 **Table 1.** Individuals included in this study

Study groups	Number of individuals after 1 <sup>st</sup> /2 <sup>nd</sup> vaccination	Median age in years	Age span in years	Gender (female/male)	Time (median) from 1 <sup>st</sup> /2 <sup>nd</sup> vaccination up to 1 <sup>st</sup> /2 <sup>nd</sup> serum sampling in days
<i>Heterologous vaccination scheme</i>					
AZD1222/BNT162b2	30/41	27	18-56	33/8	69/16
AZD1222/BNT162b2 <sup>†</sup>	-/9	43	23-56	7/2	-/14
AZD1222/mRNA-1273	1/1	45	45-45	1/0	64/14
<i>Homologous vaccination scheme</i>					
AZD1222 <sup>†</sup>	8/9	41	23-61	6/3	69/16
BNT162b2 <sup>†</sup>	8/8	35	23-51	7/1	34/14

153 † After the second vaccination, several sera were also tested for presence of virus-neutralising antibodies against the SARS-  
 154 CoV-2 delta variant of concern (B.1.617.2). For this purpose, individuals from the group of heterologous vaccinations whose  
 155 age and gender largely corresponded to those with homologous vaccinations were chosen.

156 After the first immunisation, all individuals who received an mRNA vaccine developed anti-(trimeric)-  
 157 S and anti-RBD-IgG. The vaccinees who received the AZD1222 had a prevalence of 55.3 % (anti-S IgG),  
 158 76.3% (anti-trimeric S IgG) and 94.7% (anti-RBD IgG), respectively. After administration of the second  
 159 dose, the IgG prevalence reached 100% in all groups. The mean anti-SARS-CoV-2 IgG titres varied  
 160 between 39.9 BAU/ml (anti-S IgG; first vaccination in the AZD1222/mRNA group) to 6584 BAU/ml (anti-  
 161 trimeric S IgG; second vaccination in the BNT162b2/BNT162b2 group). After the second vaccine dose,  
 162 an increase in mean anti-SARS-CoV-2 IgG titres was observed in all three study groups and in all assays.  
 163 Compared to the mean anti-SARS-CoV-2 IgG titres after the vector vaccine AZD1222 was administered  
 164 twice, the corresponding titres were 7 to 10 times higher after a heterologous vaccination and even  
 165 10 to 15 times higher according to the homologous BNT162b2 vaccination scheme (Figure 1).


166



168

169 **Figure 1:** Anti-SARS-CoV-2 immunoglobulin G (IgG) response in Binding Antibody Units (BAU) per milliliter (ml) after first (1;  
 170 empty circles) and second (2; filled circles) immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid  
 171 (mRNA)-based vaccines BNT162b2 or mRNA-1273. The cut-offs for positivity (including borderline results) of anti-trimeric  
 172 spike (S) IgG assay (A), of the anti-S IgG assay (B), and of the anti-receptor binding domain (RBD) IgG assay (C), respectively,  
 173 are marked by dashed lines. Ns: non-significant; \*: p < 0.05; \*\*: p < 0.01; \*\*\*\*: p < 0.0001 (Kruskal-Wallis test).

174 Next, we examined the development of anti SARS-CoV-2 IgG avidity in an immunoblot. After the first  
 175 vaccination, the mean avidity index was in the low to intermediate range. In contrast, high avidities  
 176 were consistently observed after administration of the second vaccine dose (Figure 2). None of the  
 177 vaccinees showed an IgG reactivity against the NP in the immunoblot (data not shown).




179

180 **Figure 2:** Development of anti-SARS-CoV-2 immunoglobulin G avidities after first (1; empty circles) and second (2; filled circles)  
 181 immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or  
 182 mRNA-1273. The measured IgG avidities were assigned to the three categories low (1), intermediate (2) and high (3) and a  
 183 mean avidity index was calculated per individual serum. Ns: non-significant; \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*\*:  $p < 0.0001$  (Kruskal-  
 184 Wallis test).

185 The virus-neutralising properties of the sera were examined with two different assays. A so-called  
 186 surrogate neutralisation test was used to investigate the extent to which the anti-RBD antibodies that  
 187 may be present in the serum are able to prevent the binding of this S-protein subunit to the human  
 188 receptor ACE2. In addition, a laboratory-developed virus-neutralisation test was used, which is based  
 189 on a VOC B.1.1.7 strain as the antigen. While the majority of the sera in the sVNT were already to be  
 190 regarded as SARS-CoV-2 neutralising after the first vaccination, these samples did not yet show any  
 191 corresponding properties in the cVNT. With both methods, however, an increase in the level of VNA  
 192 could be detected after a second vaccination. There were also marked differences between the three  
 193 vaccination groups, both in the degree of inhibition (sVNT) and in the level of VNA titres (cVNT).  
 194 Vaccinees who had received the vector vaccine only had 13- and 11-fold lower geometric mean VNA  
 195 titres (1:47) compared to individuals immunised heterologously with AZD1222/mRNA (1:608) or  
 196 homologously with BNT162b2 (1:538), respectively. However, the mean % inhibition of sVNT reached  
 197 about the same level in all three groups (Figure 3). The quantitative results of the anti-SARS-CoV-2 IgG  
 198 assays showed an almost perfect correlation to the VNA titres using VOC B.1.1.7 as antigen in the cVNT  
 199 (Pearson correlation coefficient of 0.89 to 0.91; Figure 4 A-C). In addition, from a certain anti-SARS-  
 200 CoV-2 IgG titer, it could be assumed with a high degree of probability that VNA are present. The anti-  
 201 SARS-CoV-2 IgG BAU/ml titres required for this differed between the three assays, but were all in the  
 202 three-digit range (Figure 4 D-F). The correlation between the measured values of cVNT (VOC B.1.1.7 as

203 antigen) and sVNT was somewhat less pronounced (Pearson correlation coefficient  $r$  of 0.84). It is  
 204 noticeable that especially non-neutralising sera ( $\leq 1:10$ ) were overestimated in the sVNT. This is  
 205 evidenced by the fact that the cut-off set by the manufacturer was only associated with a 4 %  
 206 probability of detecting VNA in our cVNT (Figure 5).

207




208

209

210 **Figure 3:** Development of SARS-CoV-2 neutralising antibodies (VNA) after first (1; empty circles) and second (2; filled circles)  
 211 immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or  
 212 mRNA-1273. A surrogate neutralisation assay (A) and a Vero-cell based virus-neutralisation test (cVNT) using the SARS-CoV-  
 213 2 variant of concern B.1.1.7 (alpha) strain (B) were applied to measure the VNAs. The assay cut-offs are indicated by dashed  
 214 lines. Ns: non-significant; \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.0001$  (Kruskal-Wallis test).






216

217

218 **Figure 4:** Anti-SARS-CoV-2 immunoglobulin G (IgG) response in Binding Antibody Units (BAU) per milliliter (ml) after first  
 219 (open circles) and second (filled circles) immunisation with the vector vaccine AZD1222 (green), the messenger ribonucleic  
 220 acid (mRNA)-based vaccine BNT162b2 (blue) and after a heterologous vaccination scheme, starting with AZD1222, followed  
 221 by an mRNA-based vaccine boost (BNT162b2 or mRNA-1273; red) with regard to the detection of virus-neutralising antibodies  
 222 (VNA). The latter were measured in a Vero cell-based neutralisation test (cVNT) using the SARS-CoV-2 variant of concern  
 223 B.1.1.7 (alpha). Cut-off values for positivity of the anti-trimeric spike (S) IgG assay **(A)**, anti-S IgG assay **(B)** and anti-receptor  
 224 binding domain (RBD) IgG assay **(C)**, respectively, and the cVNT cut-off value for presence of VNA are indicated by dashed  
 225 lines. The Pearson correlation coefficients  $r$  of  $\log(\text{reciprocal titre})$  were calculated with 0.89, 0.89, and 0.91, respectively. The  
 226 probability of detecting VNA at a given BAU/ml in the anti-SARS-CoV-2 IgG assays was calculated by logistic regression **(D-F)**:  
 227 VNA were present in 95% of samples when titres of 886 BAU/ml (anti-trimeric S IgG), 323 BAU/ml (anti-S IgG), and 448 BAU/ml  
 228 (anti-RBD IgG) were measured (green dashed lines; 95% confidence intervals 59.4 to 99.6%). Vertical black dashed lines  
 229 represent the threshold values set by the manufacturers of the antibody assay; red dashed lines represent the BAU/ml values  
 230 (anti-trimeric S IgG: 350 BAU/ml; anti-S IgG: 119 BAU/ml; anti-RBD IgG: 174 BAU/ml) with a 50% probability of VNA detection.

231




232

233

234 **Figure 5:** Correlation of the surrogate neutralisation test (sVNT) results with results obtained by the laboratory developed  
 235 Vero-cell based virus-neutralisation test (cVNT) using a B.1.1.7 strain as antigen **(A)**. The Pearson correlation coefficient  $r$  of  
 236  $\log(\text{reciprocal titre})$  was calculated with 0.84; empty circles; first vaccination; filled circles: second vaccination; red:  
 237 heterologous vaccination with AZD1222/mRNA; green: homologous vaccination with AZD1222; blue: homologous vaccination  
 238 with BNT162b2. Probability of detecting virus-neutralising antibodies (VNA) with the cVNT at a given % inhibition of sVNT  
 239 calculated by logistic regression **(B)**; e.g. at 20% inhibition (black dashed line), 63 % inhibition (red dashed line), and at 87%  
 240 inhibition of sVNT (green dashed line), the probabilities of detecting VNA with cVNT are 4% (95% confidence interval (CI) 1  
 241 %-16%), 50% (95% CI 34 %-66%) and 85% (95% CI 73 %-92%), respectively.

242

243 A subset of age-and gender matched sera (Table 1) obtained after the second immunisation were also  
 244 tested in the cVNT for presence of VNA against VOC B.1.617.2 (delta). In comparison to B.1.1.7, all  
 245 three vaccination groups exhibited significantly lower mean VNA titres (AZD1222/BNT162b2: 838.0 vs.  
 246 89.8, 9.3-fold lower; AZD1222/AZD1222: 47.3 vs. 9.0, 5.3-fold lower; BNT162b2/BNT162b2: 538.2 vs.  
 247 160.0, 3.4-fold lower) when B.1.617.2 is used as the antigen. If the vaccination schedule is used as a  
 248 basis, those vaccinated homologously with the vector vaccine had significantly lower mean VNAs than  
 249 those homologously vaccinated with BNT162b2. This difference was also found for the heterologous  
 250 vaccination regime. In contrast, the mean VNAs between those vaccinated homologously with  
 251 BNT162b and those vaccinated heterologously (AZD1222/BNT162b2) exhibited no measurable  
 252 difference (Figure 6).



253

254 **Figure 6:** Presence of virus-neutralising antibodies (VNA) against the SARS-CoV-2 variants of concern B.1.1.7 (alpha) and  
 255 B.1.617.2 (delta) after the second immunisation. Sera from 26 age and gender matched individuals who received a  
 256 heterologous (AZD1222/BNT162b2, n=9) or a homologous vaccination scheme (AZD1222/AZD1222, n=9;  
 257 BNT162b2/BNT162b2, n=8) were tested (see Table 1). An individual VNA titre > 1:10 was defined as neutralising in our Vero  
 258 cell-based virus neutralisation test (cVNT). † The significance of the mean VNA titre differences against B.1.1.7 and B.1.617.2  
 259 were calculated using the Wilcoxon test (\*\*: p < 0.01; \*\*\*: p < 0.001). ‡ Comparison of the mean VNA titre differences  
 260 achieved with different immunisation schemes against B.1.617.2 (Kruskal-Wallis test; ns: not significant; \*: p < 0.05; \*\*\*\*: p  
 261 < 0.0001).

262

## 263 Discussion

264 Due to the rare but serious side effects after administration of the vector vaccine, in spring 2021 the  
 265 STIKO recommended that people under the age of 60 should complete vaccinations that had already  
 266 been started with a vector vaccine with an mRNA vaccine [9, 10]. This recommendation was extended  
 267 on July 1st, 2021 to all who had already received a primary vaccination with AZD1222 [12]. In the first  
 268 quarter of this year, however, only a few animal experimental data were available on the  
 269 immunological outcome of the proposed heterologous vaccination scheme [13, 14]. Several studies  
 270 have now appeared on the immunogenicity of the heterologous vaccination scheme in humans [16,  
 271 21, 17-20].

272 In this report, we compared the development of the humoral immune response after homologous and  
 273 heterologous vaccination with different methods. To the best of our knowledge, we are one of the first

274 research groups to investigate the anti-delta VOC neutralising effect of sera after completing the  
275 heterologous immunisation regime.

276 After the first vaccination, the majority of individuals developed anti-trimeric-S, -S, and -RBD IgG  
277 antibodies, respectively. However, their titres varied between the three study groups. The results are  
278 in line with our previous study [22]. It is evident that the anti-SARS-CoV-2 IgG titres are not comparable  
279 between the three assays either. This is probably due to the different antigen preparations. In this  
280 respect, from our point of view, titre comparisons are only possible if they have been measured with  
281 the same assay.

282 The second immunisation resulted in higher titres in all three groups. It was noticeable that  
283 significantly higher anti-SARS-CoV-2 IgG titres were detected after a second vaccination with an mRNA  
284 vaccine than after the vector vaccine AZD1222 was administered again. The increase in anti-S and anti-  
285 RBD IgG titres after a second vaccination with an mRNA vaccine confirms our previous study. Due to  
286 the recommended vaccination interval of 10 to 12 weeks, we did not yet have any data on the  
287 development of the SARS-CoV-2-specific IgG antibodies after the second administration of a vector  
288 vaccine [22]. The lack of NP-specific IgG antibodies in all vaccinees can be interpreted as an indication  
289 that they had no SARS-CoV-2 infection and were therefore to be regarded as immunologically naive  
290 before immunisation [22]. It is known that vaccinations lead to particularly high anti-SARS-CoV-2 IgG  
291 titres in convalescents [27]. For these individuals, the recommendation is that they should receive a  
292 vaccine dose about six months after they have been infected [10].

293 After the first vaccination nearly all vaccinees exhibited only low to intermediate avid anti-SARS-CoV-  
294 2 IgG, while after the second vaccine dose IgG of high avidity appeared in all cases. These results  
295 confirm and expand the existing knowledge on the development of highly avid anti-SARS-CoV-2 IgG  
296 after a second vaccination with an mRNA vaccine [28]. In line with this, VNA > 1:10 against the  
297 previously prevalent SARS-CoV-2 VOC B.1.1.7 (alpha) were observed after second immunisation which  
298 confirms our recent study [22]. Marked differences in mean VNA titres were observed between  
299 individuals re-vaccinated with an mRNA vaccine and those re-vaccinated with a vector vaccine which  
300 is in accordance to animal experiments [13]. The anti-SARS-CoV-2 IgG titres obtained with three  
301 preparations of the viral S-protein correlated well with the presence and level of VNA using B.1.1.7 as  
302 the antigen in our cVNT. This observation is in line with a recently published study from Finland [29]  
303 and suggests that these standardised and easy-to-perform commercial tests are useful for  
304 demonstrating vaccination success. Anti-SARS-CoV-2 IgG titres that indicate the presence of VNA  
305 cannot, however, be defined across the board. These depend on the cVNT and the viral antigen used  
306 in it. Basically, the sVNT also showed the titre increase and evaluated all sera as virus-neutralising after  
307 the second vaccination. However, it is again noticeable that sera that are not or only weakly SARS-CoV-  
308 2-neutralising in the in-house cVNT are already evaluated as neutralising in the sVNT. This result  
309 supports our previous suggestion to raise the cut-off of the sVNT [22]. Compared to the admittedly  
310 very conservative in-house cVNT, a cut-off of over 80% would be desirable. Due to the lack of  
311 standardisation of the widespread cVNTs for the detection of VNA against SARS-CoV-2, this  
312 recommendation only applies to our laboratory and cannot be generalised.

313 From our point of view, a particularly interesting point is the significantly reduced capacity for  
314 neutralising the SARS-CoV-2 delta variant (VOC B.1.617.2) *in vitro* using a cVNT. We observed this in all  
315 26 age and gender matched individuals regardless of the immunisation regime. In addition, three of  
316 nine vaccinees who had received two doses of AZD1222 presented low or undetectable VNA against  
317 this VOC, which is considered to be 60% more transmissible than alpha [30]. The SARS-CoV-2 delta VOC  
318 is known to have accumulated a number of mutations in the S-protein. These enable continued good  
319 binding to the cellular ACE2 receptor, but at the same time lead to the viral S-protein being less  
320 efficiently recognised by antibodies [30]. The significantly lower VNA titres compared to the alpha VOC,  
321 which we and others [30, 31] observed, corroborate the suspicion of an immunescape of the delta  
322 VOC. Based on our VNA data for B.1.1.7, it can be assumed that a single vaccination is not sufficient to  
323 induce measurable VNA against B.1.617.2.

324 The results presented by us on the antibody response after heterologous SARS-CoV-2 vaccination are  
325 consistent with the few available clinical studies [17, 19, 21, 16, 18, 20]. In June 2021, a randomised  
326 study from Spain has already demonstrated that the heterologous vaccination scheme is suitable for  
327 generating a robust immune response. Unfortunately, this very extensive work did not include a  
328 control group of individuals who received two immunisations with the vector vaccine [21]. A recent  
329 preprint reports significant higher anti-S antibody titres in a group of 26 individuals who first received  
330 an AZD1222 vaccination followed by re-vaccination with BNT162b2 compared to 14 individuals that  
331 were vaccinated twice with BNT162b2. However, these results were obtained with a total antibody  
332 assay which does not discriminate between IgG and acute phase immunoglobulin M. Furthermore,  
333 markedly higher VNA titres were observed in the AZD1222/BNT162b2 group using chimeric vesicular  
334 stomatitis viruses carrying the S-proteins of SARS-CoV-2 VOCs B.1.1.7 (alpha) or B.1.351 (beta),  
335 respectively, as antigens. However, data after homologous vaccination with the vector vaccine are  
336 missing in this preliminary report [16]. In another investigation [18], differences in the anti-S IgG and  
337 VNA titres were not observed after heterologous vaccination (AZD1222/mRNA) or after homologous  
338 vaccination with an mRNA vaccine. In contrast, both parameters were significantly lower after  
339 homologous vaccination with the vector vaccine. These results are in agreement with our data even if  
340 only one IgG assay and one sVNT were used by this research group [18]. The results of a single-blind  
341 randomised British study, in which the four possible vaccine combinations of AZD1222 and BNT162b2  
342 were compared with one another, are very interesting and promising. These researchers report about  
343 9-fold higher mean anti-S IgG titres in sera from heterologous AZD1222/BNT162b2 vaccinees  
344 compared to individuals immunised twice with AZD1222 [19] which is largely in accordance to our  
345 results. In a study from Sweden, markedly higher anti-S and anti-RBD IgG titres were observed after  
346 heterologous vaccination (AZD1222/mRNA-1273) compared to the homologues AZD1222 scheme. In  
347 line with this the occurrence of significantly higher VNA titres both against a wild-type SARS-CoV-2 and  
348 against a VOC B.1.351 (beta) strain were demonstrated for these vaccinees [20]. One investigation  
349 reports the development of high IgG avidity after completion of a homologous (AZD1222/AZD1222;  
350 BNT162b2/BNT162b2) or heterologous SARS-CoV-2 (AZD1222/BNT162b2) immunisation scheme.  
351 While there were no qualitative differences in the development of IgG avidity between both groups,  
352 the AZD1222/BNT162b2 vaccinees developed a significantly higher relative avidity index [17]. In our

353 assay we cannot investigate such gradual differences. Furthermore, the authors report markedly lower  
354 anti-SARS-CoV-2 IgG and VNA (against VOCs alpha and beta) titres in the AZD1222/AZD1222 group  
355 [17].

356 It is not yet sufficiently clear why homologous vaccination with the AZD1222 vector vaccine leads to  
357 lower anti-SARS-CoV-2 IgG and VNA titres. A possible explanation could be the immune response to  
358 the adenovirus vector backbone (so called “antivector immunity” [3]).

359 The work presented by us contributes to a better understanding of the humoral immunogenicity of  
360 the heterologous SARS-CoV-2 vaccination regimen. With various assays we monitored the  
361 development of anti S-specific IgG antibodies and make statements about their binding-strength as an  
362 expression of maturity. In addition, with a commercial and an in-house test, we showed that VNA can  
363 be detected after the second vaccination and that VNA titres vary in dependence of the viral antigen.

364 Important limitations of our report are (i) the heterogeneity of the study groups, (ii) the small group  
365 size of individuals who received a homologous vaccination scheme, (iii) the subjects, who are  
366 predominantly in younger to middle adulthood, (iv) the lack of information on the durability of the  
367 detected antibodies, and (v) the missing consideration of cellular and innate immunity after  
368 immunisation. Therefore, among other things, no statements can be made from our data about the  
369 need for further booster vaccinations. In addition, no better protection against SARS-CoV-2 infections  
370 can be derived from the level of the antibody titre *per se*.

371 In summary, the administration of a vector vaccine followed by an mRNA vaccine boost resulted in a  
372 strong humoral immune response, comparable to that after two immunisations with an mRNA vaccine.  
373 Regardless of the vaccination scheme, all individuals developed highly avid anti-SARS-CoV-2 IgGs. Even  
374 if almost all vaccinees presented VNA after the second immunisation, the generally lower titres  
375 indicate a partial immune escape of the delta VOC.

376

377

378 **Availability of data:** The data presented in this study are available on request from the  
379 corresponding author.

380 **Ethics approval and consent to participate:** The study was conducted according to the guidelines of  
381 the Declaration of Helsinki, and approved by the Ethics Committee of the medical faculty of the  
382 Christian-Albrechts-Universität zu Kiel, Kiel, Germany (D467/20, 16.04.2020; amendment 02.02.2021).  
383 Informed consent was obtained from all subjects involved in the study.

384 **Consent for publication:** Not applicable.

385 **Competing interests:** The companies Diasorin GmbH, Mikrogen GmbH and Tecomedical GmbH  
386 supported this study by providing free or discounted kits. None of the three companies had any  
387 influence on the testing and the interpretation of the results. The authors declare that they have no  
388 competing interests.

389 **Author Contributions:** AK, FN, and RR had full access to all the data in the study and take responsibility  
390 for the integrity of the data and the accuracy of the data analysis. Concept and design: AK. Acquisition,  
391 analysis, or interpretation of the data: all authors. Drafting of the manuscript: AK, HF and RR. Critical  
392 revision of the manuscript for important intellectual content: all authors. All authors have read and  
393 agreed to the published version of the manuscript.

394 **Funding:** This research received no external funding.

395 **Acknowledgments:** The authors would like to thank all volunteers for participating in the study.

396

397

398 **References**

- 399 1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol.*  
400 2021;19(3):141-54. doi:10.1038/s41579-020-00459-7.
- 401 2. Klasse PJ, Nixon DF, Moore JP. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in  
402 nonhuman primates and humans. *Sci Adv.* 2021;7(12). doi:10.1126/sciadv.abe8065.
- 403 3. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced  
404 protection against COVID-19 in humans. *Nat Rev Immunol.* 2021;21(8):475-84. doi:10.1038/s41577-  
405 021-00578-z.
- 406 4. Krammer F. SARS-CoV-2 vaccines in development. *Nature.* 2020;586(7830):516-27.  
407 doi:10.1038/s41586-020-2798-3.
- 408 5. Cines DB, Bussel JB. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. *N Engl J*  
409 *Med.* 2021;384(23):2254-6. doi:10.1056/NEJMe2106315.
- 410 6. Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies:  
411 a comprehensive review of phase 3 candidates. *NPJ Vaccines.* 2021;6(1):28. doi:10.1038/s41541-021-  
412 00292-w.
- 413 7. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. *JAMA.* 2021;325(13):1318-20.  
414 doi:10.1001/jama.2021.3199.
- 415 8. EU. Safe COVID-19 vaccines for Europeans. 2021. [https://ec.europa.eu/info/live-work-travel-](https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans_en)  
416 [eu/coronavirus-response/safe-covid-19-vaccines-europeans](https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans_en) en. Accessed 12 May 2021.
- 417 9. STIKO. Stellungnahme der Ständigen Impfkommission zum Zeitpunkt der Gabe eines mRNA-  
418 Impfstoffs nach Erstimpfung mit AstraZeneca Vaccine (Vaxzevria) bei <60-Jährigen. 2021.  
419 [https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-](https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-Impfabstand.html)  
420 [Impfabstand.html](https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-Impfabstand.html). Accessed 12 May 2021.
- 421 10. RKI. Mitteilung der Ständigen Impfkommission beim Robert Koch-Institut Beschluss der STIKO zur  
422 7. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung.  
423 *Epidemiologisches Bulletin.* 2021;25:3-13.
- 424 11. Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C et al. A dynamic nomenclature  
425 proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol.* 2020;5(11):1403-7.  
426 doi:10.1038/s41564-020-0770-5.
- 427 12. STIKO. Mitteilung der STIKO zur COVID-19-Impfung: Impfabstand und heterologes Impfschema  
428 nach Erstimpfung mit Vaxzevria (1.7.2021). 2021.  
429 [https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/PM\\_2021-07-01.html](https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/PM_2021-07-01.html).  
430 Accessed 2 July 2021.
- 431 13. Spencer AJ, McKay PF, Belij-Rammerstorfer S, Ulaszewska M, Bissett CD, Hu K et al. Heterologous  
432 vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune  
433 responses in mice. *Nat Commun.* 2021;12(1):2893. doi:10.1038/s41467-021-23173-1.
- 434 14. He Q, Mao Q, An C, Zhang J, Gao F, Bian L et al. Heterologous prime-boost: breaking the protective  
435 immune response bottleneck of COVID-19 vaccine candidates. *Emerg Microbes Infect.* 2021;10(1):629-  
436 37. doi:10.1080/22221751.2021.1902245.
- 437 15. Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD et al. Heterologous prime-  
438 boost COVID-19 vaccination: initial reactogenicity data. *Lancet.* 2021;397(10289):2043-6.  
439 doi:10.1016/S0140-6736(21)01115-6.



440 16. Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D et al. Heterologous ChAdOx1 nCoV-  
441 19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell  
442 reactivity. medRxiv. 2021:2021.05.30.21257971. doi:10.1101/2021.05.30.21257971.

443 17. Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C et al. Safety, reactogenicity,  
444 and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1  
445 nCoV-19 and BNT162b2: a prospective cohort study. *Lancet Respir Med*. 2021. doi:10.1016/S2213-  
446 2600(21)00357-X.

447 18. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S et al. Immunogenicity and reactogenicity  
448 of heterologous ChAdOx1 nCoV-19/mRNA vaccination. *Nature Medicine*. 2021. doi:10.1038/s41591-  
449 021-01464-w.

450 19. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ et al. Safety and immunogenicity of  
451 heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA  
452 COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *Lancet*. 2021.  
453 doi:10.1016/S0140-6736(21)01694-9.

454 20. Normark J, Vikstrom L, Gwon YD, Persson IL, Edin A, Bjorsell T et al. Heterologous ChAdOx1 nCoV-  
455 19 and mRNA-1273 Vaccination. *N Engl J Med*. 2021. doi:10.1056/NEJMc2110716.

456 21. Borobia AM, Carcas AJ, Perez-Olmeda M, Castano L, Bertran MJ, Garcia-Perez J et al.  
457 Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants  
458 (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet*.  
459 2021;398(10295):121-30. doi:10.1016/S0140-6736(21)01420-3.

460 22. Neumann F, Rose R, Rompke J, Grobe O, Lorentz T, Fickenscher H et al. Development of SARS-CoV-  
461 2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination.  
462 *Vaccines (Basel)*. 2021;9(7):700. doi:10.3390/vaccines9070700.

463 23. Bonelli F, Blocki FA, Bunnell T, Chu E, De La OA, Grenache DG et al. Evaluation of the automated  
464 LIAISON((R)) SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. *Clin Chem Lab*  
465 *Med*. 2021;59(8):1463-7. doi:10.1515/cclm-2021-0023.

466 24. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K et al. WHO International  
467 Standard for anti-SARS-CoV-2 immunoglobulin. *Lancet*. 2021;397(10282):1347-8. doi:10.1016/S0140-  
468 6736(21)00527-4.

469 25. Stromer A, Rose R, Grobe O, Neumann F, Fickenscher H, Lorentz T et al. Kinetics of Nucleo- and  
470 Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2  
471 Infection. *Microorganisms*. 2020;8(10). doi:10.3390/microorganisms8101572.

472 26. Stromer A, Rose R, Schafer M, Schon F, Vollersen A, Lorentz T et al. Performance of a Point-of-Care  
473 Test for the Rapid Detection of SARS-CoV-2 Antigen. *Microorganisms*. 2020;9(1).  
474 doi:10.3390/microorganisms9010058.

475 27. Frieman M, Harris AD, Herati RS, Krammer F, Mantovani A, Rescigno M et al. SARS-CoV-2 vaccines  
476 for all but a single dose for COVID-19 survivors. *EBioMedicine*. 2021;68.  
477 doi:10.1016/j.ebiom.2021.103401.

478 28. Struck F, Schreiner P, Staschik E, Wochinz-Richter K, Schulz S, Soutschek E et al. Vaccination versus  
479 infection with SARS-CoV-2: Establishment of a high avidity IgG response versus incomplete avidity  
480 maturation. *J Med Virol*. 2021. doi:10.1002/jmv.27270.

- 481 29. Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R et al. COVID-19  
482 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. *Nature*  
483 *Communications*. 2021;12(1):3991. doi:10.1038/s41467-021-24285-4.
- 484 30. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM et al. Reduced sensitivity  
485 of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*. 2021;596(7871):276-80.  
486 doi:10.1038/s41586-021-03777-9.
- 487 31. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C et al. Neutralising antibody activity against  
488 SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *Lancet*. 2021;397(10292):2331-3.  
489 doi:10.1016/S0140-6736(21)01290-3.

490

491